ID   NK-92CI
AC   CVCL_U271
SY   NK-92 ci; NK92CI; NK-92 transfected with pCEP4-LTR-hIL2
DR   ATCC; CRL-2409
DR   BioSample; SAMN03471837
DR   Wikidata; Q54930657
RX   Patent=US8034332;
RX   PubMed=10365666;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6672.
CC   Population: Caucasian.
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:6001; IL2.
CC   Caution: NantKwest exclusively owns, controls and distributes this cell line.
CC   Discontinued: ATCC; CRL-2409; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: Natural killer cell; CL=CL_0000623.
ST   Source(s): ATCC=CRL-2409
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 9,12
ST   D16S539: 11,12
ST   D5S818: 12,13
ST   D7S820: 10,11
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 16,18
DI   NCIt; C82217; Natural killer cell lymphoblastic leukemia/lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2142 ! NK-92
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 19-12-24; Version: 16
//
RX   PubMed=10365666; DOI=10.1089/10430349950018030;
RA   Tam, Ying K.
RA   Maki, Guitta
RA   Miyagawa, Blythe
RA   Hennemann, Burkhard
RA   Tonn, Torsten
RA   Klingemann, Hans-Georg
RT   "Characterization of genetically altered, interleukin 2-independent
RT   natural killer cell lines suitable for adoptive cellular
RT   immunotherapy.";
RL   Hum. Gene Ther. 10:1359-1373(1999).
//
RX   Patent=US8034332;
RA   Klingemann, Hans-Georg
RT   "Interleukin-secreting natural killer cell lines and methods of use.";
RL   Patent number US8034332, 11-Oct-2011.
//